These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18480698)

  • 1. Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms.
    López-Torres E; Salomón J; Vicario F; Peñas-Lledó E; Dorado P; Llerena A
    J Clin Psychopharmacol; 2008 Jun; 28(3):352-3. PubMed ID: 18480698
    [No Abstract]   [Full Text] [Related]  

  • 2. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
    Kwon JS; Kim E; Kang DH; Choi JS; Yu KS; Jang IJ; Shin SG;
    Eur Neuropsychopharmacol; 2008 Dec; 18(12):897-907. PubMed ID: 18786813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis.
    Evcimen H; Alici-Evcimen Y; Basil B; Mania I; Mathews M; Gorman JM
    J Psychiatr Pract; 2007 Mar; 13(2):117-9. PubMed ID: 17414689
    [No Abstract]   [Full Text] [Related]  

  • 4. [Aripiprazole induced Parkinsonism: A case report].
    Pasquier de Franclieu S; Germain C; Petitjean F
    Encephale; 2009 Oct; 35(5):496-8. PubMed ID: 19853725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of delusional disorder with low-dose aripiprazole.
    Miyamoto S; Miyake N; Ogino S; Endo T; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):369. PubMed ID: 18588606
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
    Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
    J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole.
    Koener B; Hermans E; Maloteaux JM; Jean-Jean A; Constant EL
    Am J Psychiatry; 2007 Sep; 164(9):1437-8. PubMed ID: 17728432
    [No Abstract]   [Full Text] [Related]  

  • 9. Antipsychotic dosing: still a work in progress.
    Remington G
    Am J Psychiatry; 2010 Jun; 167(6):623-5. PubMed ID: 20516160
    [No Abstract]   [Full Text] [Related]  

  • 10. [Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
    Slooff CJ; Arends J
    Ned Tijdschr Geneeskd; 2006 Feb; 150(7):400-1; author reply 401. PubMed ID: 16523806
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
    Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
    J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
    Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
    Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
    Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.
    Adan-Manes J; Garcia-Parajua P
    J Clin Pharm Ther; 2009 Apr; 34(2):245-6. PubMed ID: 19250146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole. Abilitat, OPC 14597.
    Drugs R D; 2002; 3(1):25-7. PubMed ID: 11881525
    [No Abstract]   [Full Text] [Related]  

  • 16. Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient.
    Saddichha S; Kumar R; Babu GN; Chandra P
    J Clin Pharmacol; 2012 Sep; 52(9):1448-9. PubMed ID: 21903892
    [No Abstract]   [Full Text] [Related]  

  • 17. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.
    Chen SF; Shen YC; Chen CH
    Psychopharmacology (Berl); 2009 Aug; 205(2):285-92. PubMed ID: 19387614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole-induced parkinsonism.
    Sharma A; Sorrell JH
    Int Clin Psychopharmacol; 2006 Mar; 21(2):127-9. PubMed ID: 16421466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole associated with severe exacerbation of Parkinson's disease.
    Wickremaratchi M; Morris HR; Ali IM
    Mov Disord; 2006 Sep; 21(9):1538-9. PubMed ID: 16817207
    [No Abstract]   [Full Text] [Related]  

  • 20. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.